Pharming Group N.V.

PHARM

NL0010391025

Pharmaceuticals

Market Closed - Euronext Amsterdam Other stock markets 16:35:08 28/05/2024 BST			5-day change	1st Jan Change
0.8445 ^EUR	+2.18%		+3.68%	-18.09%

05-21	Transcript : Pharming Group N.V. - Shareholder/Analyst Call
05-08	Transcript : Pharming Group N.V., Q1 2024 Earnings Call, May 08, 2024

Pharming Group N.V. Announces Resignation of Rienk Pijpstra from the Board of Management, Effective on September 1, 2012

June 19, 2012 at 06:42 am

Pharming Group NV announced that its Chief Medical Officer Dr. Rienk Pijpstra has resigned from the Board of Management, and will leave the company on September 1, 2012.

Latest news about Pharming Group N.V.

Transcript : Pharming Group N.V. - Shareholder/Analyst Call	05-21
Transcript : Pharming Group N.V., Q1 2024 Earnings Call, May 08, 2024	05-08
Pharming Group N.V. Provides Revenue Guidance for 2024	05-08	CI
Pharming Group N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Pharming Group to Buy Back EUR123 Million of Bonds due 2025	04-22	MT
Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds	04-18	MT
Pharming Group N.V. announced that it expects to receive ?100 million in funding	04-17	CI
Pharming Group N.V. Announces Completion of Enrollment in Pediatric Clinical Trial of Leniolisib	04-08	CI
Pharming Group Finishes Enrolling Patients for Phase 3 Pediatric Testing of its Treatment for Rare Auto-Immune Disorder	04-08	MT
Pharming Group N.V. Provides Earnings Guidance for the Year 2024	03-14	CI
Pharming Group Seeks Acquisitions	03-14	CI
Transcript : Pharming Group N.V., Q4 2023 Earnings Call, Mar 14, 2024	03-14
Pharming Group N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-14	CI
Pharming Group N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
RBC Raises Price Target on Pharming Group to EUR2.10 From EUR1.95, Keeps Outperform Rating	01-09	MT
Pharming Group Announces Development Plans for Leniolisib for Additional Primary Immunodeficiencies	12-15	CI
Pharming Group Plans Phase 2 Trial for Immune System Drug in 2024	12-13	MT
Pharming Group Plans to Develop Leniolisib for Additional Primary Immunodeficiencies Following Engagement With FDA	12-13	MT
Pharming Group Expects EU Panel Opinion in 2024 for Rare Immunodeficiency Treatment	11-10	MT
Transcript : Pharming Group N.V., Q3 2023 Earnings Call, Oct 26, 2023	26/10/23
Pharming Group N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/10/23	CI
Pharming Group N.V. Appoints Richard Peters as Non-Executive Director	25/09/23	CI
Transcript : Pharming Group N.V. - Shareholder/Analyst Call	25/09/23
ADRs Advance, Warrantee Inc. Climbs 20.0%	22/09/23	DJ
ADRs Close Lower; Quantasing Group Ltd. Declines 33.5%	21/09/23	DJ

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The Group is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming Group N.V. serves patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia/Pacific.

Sector

Pharmaceuticals

Calendar

01/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Pharming Group N.V.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8445 EUR

Average target price

1.933 EUR

Spread / Average Target

+128.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHARMING GROUP N.V.	-18.09%	619M
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	347B
MERCK & CO., INC.	+15.66%	319B
ABBVIE INC.	+0.24%	274B
ASTRAZENECA PLC	+13.47%	238B
NOVARTIS AG	+7.35%	204B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+4.23%	161B
PFIZER, INC.	-1.70%	160B

Other Pharmaceuticals